Eisai Co., Ltd.

Eisai Co., Ltd. is a Japanese pharmaceutical company that engages in the research, development, manufacturing, and marketing of ethical drugs. Its product portfolio includes treatments for neurological disorders such as Alzheimer's disease and oncology indications. The company serves patients and healthcare providers in Japan as well as in international markets across North America, Europe, and Asia. Eisai’s business activities are centered on delivering innovative medicines that address unmet medical needs.

The firm maintains a global operational footprint with research and development centers, manufacturing sites, and sales offices located in several countries. While specific employee or revenue figures are not provided in the source material, Eisai is recognized as one of the leading pharmaceutical enterprises headquartered in Japan. Its international presence enables it to conduct clinical trials and commercialize products across diverse regulatory environments. The company’s headquarters remain in Japan, reflecting its origins and primary administrative base.

Eisai distinguishes itself through a strategic focus on neurology and oncology, areas in which it has brought several notable therapies to market. Examples include the Alzheimer’s treatment Aricept (donepezil) and the multi‑targeted kinase inhibitor Lenvima (lenvatinib) used in various cancer indications. This therapeutic specialization is supported by a strong emphasis on scientific innovation and collaboration with academic and clinical partners. The company also adheres to stringent regulatory standards governing drug safety and efficacy in the jurisdictions where it operates.

Structurally, Eisai operates as an independent, publicly listed corporation whose shares are traded on the Tokyo Stock Exchange. It maintains a network of wholly owned subsidiaries and affiliated entities that support its regional operations and product distribution. Ownership remains dispersed among institutional and individual investors, with no single parent entity disclosed in the available information. This corporate structure allows Eisai to consolidate global functions while preserving local market responsiveness.